NeuroSense links PrimeC to Alzheimer’s biomarkers, but can three patients justify another trial?
NeuroSense Therapeutics says PrimeC produced biomarker changes consistent with its multi-target mechanism in an exploratory Alzheimer’s study, but an exceptionally small dataset leaves clinical efficacy, safety and commercial relevance unanswered.